Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 18.12 billion Danish Kroner [US$2.74 billion]
of which 17%
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
(445.48 billion Hungarian Forints [US$1.58 billion]
based in France
(2.35 billion Euro [US$2.65 billion]
During the year ended December of 2018, sales at
Lonza Group AG were 5.54 billion Swiss Francs (US$5.51 billion).
increase of 8.6%
versus 2017, when the company's sales were 5.11 billion Swiss Francs.
This was the fifth consecutive year of sales increases at Lonza Group AG
(and since 2013, sales have increased a total of 55%).